This FAQ explains how aseptic processing, contamination control, and validation protect patients amid sterile injectable failures.
|Articles|September 1, 2018
- BioPharm International-09-01-2018
- Volume 31
- Issue 9
Lightweight Actuator for Aseptic Valves
Watson-Marlow Fluid Technology Group added a new actuator suitable for applications where reduced weight is a concern.
Advertisement
Watson-Marlow Fluid Technology Group added a new GMP-compliant actuator to its AKS Actuator series for ASEPCO Weirless Radial diaphragm in-line-valves. The lightweight actuator is suited for applications where reduced weight is a concern.
The actuator design combines a plastic body with a stainless-steel diaphragm interface and requires fewer brackets or ancillaries for installation, according to the company.Each component has laser-etched serial numbers for full traceability and carries a three-year warranty.
Articles in this issue
about 8 years ago
FDA Seeks to Enhance Manufacturing of Cell and Gene Therapiesabout 8 years ago
Automated Single-Use System for Filtration and Product Dispensingabout 8 years ago
Be a Part of the Solutionabout 8 years ago
Evaluating the Rewards vs. the Risks of Automationabout 8 years ago
Checking Incoming Goodsabout 8 years ago
Biopharma Demand Continues to Influence CMO Actionsabout 8 years ago
QbD in the Development of ADCs with PBD Dimer Warheadsabout 8 years ago
Patenting Antibodies in Europeabout 8 years ago
Elements in Raw Materials May Impact Product QualityAdvertisement
Related to this article
Bimekizumab-bkzx (Bimzelx) produced ACR50 joint responses in 54.9% of psoriatic arthritis patients at week 24 vs 43.8% with risankizumab.
VG801 gene therapy improved vision through 12 months in a Stargardt disease trial as VeonGen aligned with FDA on its pivotal phase 3 design.
Matt Trupo, Richard Jaenisch, and Brian Drapeau explore how AI advances biological insights, drug-target discovery, and supply chains.
As access to low Earth orbit expands, space-based research is opening possibilities in drug discovery, formulation, and manufacturing. In Part 1, the authors look at how microgravity changes biology and chemistry in ways that can’t be reproduced on Earth and where it fits from target discovery to life cycle management.
Aldevron and IDT added PE Ultra prime editor mRNA and 6 ABE8e base editor mRNAs to help researchers edit DNA without double-strand breaks.
Advertisement
Advertisement
Trending on BioPharm International
1
Blackstone to Provide Pfizer Up to $1.5 Billion for Monthly GLP-1 Berobenatide Development
2
ImvivaBio’s Dual-Target Allogeneic CAR-T Sustains Lupus Remission Through 12 Months
3
Updates on Simtra BioPharma Solutions’ Bloomington Capacity Expansions
4
The BioPharm Brief: An AI-Designed Multibody ADC Enters the Clinic, Blackstone Backs Pfizer’s Monthly GLP-1, and enGene Readies a Bladder Cancer BLA
5